Toxicity and Outcomes of the KEYNOTE-522 Chemo-immunotherapy Regimen in Non-Metastatic Triple-negative Breast Cancer," for consideration for publication in the

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Introduction Real-world implementation of the KEYNOTE-522 regimen presents substantial challenges, including high treatment-modification burden and adherence barriers, particularly in community and non-trial settings. Methods We conducted a retrospective cohort analysis of stage II-III TNBC patients treated at the University of Nebraska Medical Center from 2018–2024. Patients receiving neoadjuvant pembrolizumab with chemotherapy (KEYNOTE-522 regimen) (N = 50) were compared with a historical control group receiving dose-dense anthracycline-cyclophosphamide-taxane (ddACT) chemotherapy alone (N = 28). The primary focus was evaluating treatment-related toxicities, adherence challenges, pathologic complete response (pCR), and implications for surgical decision-making and clinical practice. Results Among 78 patients, 50 received the KEYNOTE-522 regimen and 28 received ddACT. High treatment-modification burden was more frequent in the pembrolizumab group, as reflected by treatment modifications or discontinuations (50.0% vs. 17.9%, p = 0.0051). pCR rates were higher with pembrolizumab (42.0% vs. 28.6%, p = 0.2391), and all pCRs corresponded to RCB 0. Recurrence occurred exclusively in non-pCR patients. At 12 months, recurrence and mortality were lower in the pembrolizumab group (16.0% vs. 44.4%, p = 0.0367; 8.0% vs. 29.6%, p = 0.0777), despite shorter median follow-up (17.7 vs. 40.4 months). EFS did not differ significantly by treatment (p = 0.1240), but was strongly associated with RCB class (p = 0.0118) and prognostic stage (p < 0.0001). In ddACT patients, treatment modification predicted worse EFS (p = 0.0215). No demographic or clinical variables were independently associated with pCR. Conclusions In this real-world cohort, the KEYNOTE-522 regimen was associated with high treatment-modification burden and adherence challenges, particularly among medically and socially complex patients. These findings suggest that implementing pembrolizumab outside clinical trials may require biomarker-guided patient selection and equity-focused implementation strategies before routine adoption in under-resourced settings.

Article activity feed